119-HR-3164 Investigative Journalist Impact Analysis

Summary

Neutral, evidence‑driven assessment of likely impacts if H.R. 3164 (“Ensuring Community Access to Pharmacist Services Act”) becomes law on January 1, 2026. Core mechanism: create Medicare Part B coverage and payment for defined pharmacist services (test‑and‑treat for specified respiratory infections; qualifying services during federally declared public‑health emergencies), with assignment/balance‑billing limits. [1]Congress.gov / GPO — BILLS-119hr3164ih.pdf (Official bill text)

• Access likely improves for Medicare beneficiaries seeking rapid testing/treatment for flu, COVID‑19, RSV, and strep; pharmacists could bill Part B directly where state law allows service provision/collaboration. [1]Congress.gov / GPO — BILLS-119hr3164ih.pdf (Official bill text)
• Clinical upside is plausible for time‑sensitive antivirals (e.g., Paxlovid) when access delays are reduced; real‑world data associate Paxlovid prescribing with ~51% lower COVID‑19 hospitalization risk. [2]CDC MMWR — Paxlovid Associated with Decreased Hospitalization Rate — MMWR 71(48…
• Budget effects are uncertain: creating a new payable site‑of‑care may both substitute for costlier settings and induce new use; prior evidence for similar low‑acuity access points shows net spending increases in many contexts. [3]Health Affairs (via PubMed) — Retail Clinic Visits For Low‑Acuity Conditions In…
• Equity impacts are mixed: pharmacies are geographically close for most Americans, but access gaps persist where closures or “pharmacy deserts” are concentrated in Black/Latino neighborhoods; telepharmacy policies can mitigate some gaps. [4]University of Pittsburgh (CP3) — Access to community pharmacies: nationwide GIS…

Economic Effects

What changes in spending, revenues, and market behavior are plausible if Medicare pays pharmacists for narrowly defined services?

• New payable benefit under Part B: Pharmacist services (evaluation/management for testing or treatment of COVID‑19, influenza, RSV, strep; plus PHE‑tied services) would be paid at 80% of the lesser of the charge or 85% of the Physician Fee Schedule (100% when addressing a declared PHE public‑health need). Balance billing is prohibited. Effective for services on/after January 1, 2026. [1]Congress.gov / GPO — BILLS-119hr3164ih.pdf (Official bill text)
• Utilization and total spending: Expanded convenient access points often generate new visits in addition to substituting for pricier sites. A Health Affairs study found retail‑clinic use for low‑acuity conditions increased spending by ~21% due to new utilization, even after accounting for substitution from physician offices/ED. This dynamic could analogously affect pharmacist‑billed test‑and‑treat. [3]Health Affairs (via PubMed) — Retail Clinic Visits For Low‑Acuity Conditions In…
• Potential substitution/diversion: Evidence on ED diversion from nearby retail clinics is mixed—some quasi‑experimental work shows reductions in avoidable ED use, while other studies show little or no change—so net savings from substitution are uncertain. [6]Economics Letters (Elsevier) — Check up before you check out: Retail clinics an…
• Chronic‑care externalities: Although this bill is limited to acute respiratory/test‑and‑treat and PHE services, pharmacist integration more broadly improves blood‑pressure control and other risk factors in randomized trials, with updated meta‑analysis through 2024; U.S. modeling suggests pharmacist‑prescribing for hypertension can be cost‑effective at conventional thresholds. Spillover benefits are plausible where collaborative practice enables follow‑up/referral. [7]Frontiers in Pharmacology (PMC) — Pharmacists delivering hypertension care serv…
• Pharmacy revenue and viability: Nearly one‑third of retail pharmacies operating in 2010–2021 had closed by 2021, disproportionately in Black/Latino and lower‑income areas. New Medicare service revenue could modestly stabilize some sites, but impacts will depend on state scope, payer mix, and uptake. [8]JAMA — Nearly 1 in 3 US Pharmacies Have Closed Since 2010, Widening Access Gaps
• No posted federal score: As of May 23, 2026, Congress.gov shows no CBO cost estimate for H.R. 3164, adding budget uncertainty. [5]Congress.gov / Library of Congress — H.R. 3164 – Congress.gov overview (status;…

Social Effects

Who benefits or bears risk under the proposal?

• Access in shortage areas: Over 101.7 million people live in primary‑care Health Professional Shortage Areas (HPSAs). Enabling pharmacists to bill Part B for narrow acute services can expand same‑day care options where primary‑care appointment supply is tight. [9]HRSA Data — HRSA Designated HPSA Quarterly Summary (as of Mar 31, 2026)
• Proximity advantage vs. uneven availability: Nationwide, ~88.9% of people live within 5 miles of a community pharmacy, but closures since 2010 and persistent “pharmacy deserts” mean gains will be smaller in specific urban minority neighborhoods unless mitigated (e.g., telepharmacy). [4]University of Pittsburgh (CP3) — Access to community pharmacies: nationwide GIS…
• Timely antiviral access and disparities: Pharmacists’ ability to prescribe Paxlovid under FDA’s EUA, combined with billable testing/treatment, can reduce delays for high‑risk patients; real‑world data associate Paxlovid prescriptions with ~51% lower hospitalization. Prior studies found lower Paxlovid prescribing among Black, Hispanic/Latino, and some other racial/ethnic groups—expanding access points may help narrow such gaps if implemented equitably. [10]Axios (FDA EUA news) — FDA allows pharmacists to prescribe Paxlovid (EUA revisi…
• Older adults and caregivers: Pharmacy‑based vaccination and acute care are associated with convenience and improved uptake for older adults; billable pharmacist encounters may reduce transportation/wait burdens for Medicare beneficiaries. [11]Vaccine (Elsevier) via PMC — Characteristics of older Medicare beneficiaries re…
• State‑law filter on equity: Because the bill defers to state scope and collaboration rules, a Medicare patient’s access will still vary by state (e.g., standing orders or protocols for flu/strep in some states). [12]NCDHHS — NC standing orders enabling pharmacist flu test‑and‑treat (2025)

Environmental Effects

Direct environmental provisions are absent, but care‑pathway shifts can have small secondary effects.

• Shorter trips, marginal emissions savings: Most adults live close to a pharmacy; substituting some urgent low‑acuity trips from distant clinics/EDs to nearby pharmacies can trim vehicle miles traveled. EPA estimates ~400 g CO2 per mile for a typical passenger vehicle, so even a few miles avoided per visit creates small but real reductions at scale. [4]University of Pittsburgh (CP3) — Access to community pharmacies: nationwide GIS…
• Resource intensity: Treating low‑acuity respiratory infections in outpatient pharmacy settings is generally less resource‑intensive than ED care (fewer diagnostics/overhead), suggesting lower per‑visit environmental footprint, although robust U.S. life‑cycle comparisons are limited. (Inference based on site‑of‑care resource profiles; empirical environmental LCA data are sparse.)

Temporal Analysis

What shifts occur immediately versus over time?

• Near term (from Jan 1, 2026): Pharmacies in states with enabling laws and collaboration protocols can begin billing Part B for qualifying test‑and‑treat services; payments follow PFS‑linked rates and assignment rules. [1]Congress.gov / GPO — BILLS-119hr3164ih.pdf (Official bill text)
• Medium term (1–3 years): Uptake will hinge on state scope reforms, payer alignment beyond Medicare, and workflow capacity; PREP Act extensions keep vaccination authority broad through 2029, supporting sustained pharmacy‑based respiratory care infrastructure. [13]National Alliance of State Pharmacy Associations (NASPA) — Pharmacist/Technicia…
• Long term (>3 years): If pharmacist access reduces delays for time‑sensitive antivirals and improves vaccination reach, avoidable hospitalizations could decline modestly; however, total spending pathways remain ambiguous given historical evidence of new utilization at convenient care sites. [2]CDC MMWR — Paxlovid Associated with Decreased Hospitalization Rate — MMWR 71(48…

Unintended Consequences / Risks

Documented or credible risks to monitor if implemented.

• Induced demand and spending drift: Easier access can increase encounter volume for self‑limited conditions, raising spending despite lower unit prices—observed with retail clinics. Program integrity and appropriate‑use guardrails will matter. [3]Health Affairs (via PubMed) — Retail Clinic Visits For Low‑Acuity Conditions In…
• Fragmentation and continuity: Shifting acute visits away from primary‑care practices may modestly reduce continuity for some patients; evidence on system‑level substitution vs. add‑on use is mixed. [14]pmc.ncbi.nlm.nih.gov
• Antimicrobial stewardship: Pharmacist‑managed strep/URI care must align with testing algorithms and stewardship best practices; historically, ~30% of U.S. outpatient antibiotic prescriptions were unnecessary, underscoring the need for protocolized prescribing and safety‑netting. [15]jamanetwork.com
• Uneven state scope: Benefits will accrue inequitably if states lack standing orders/protocols for test‑and‑treat. Early movers (e.g., NC standing order; Arkansas statewide protocol) illustrate the enabling policy pattern. [12]NCDHHS — NC standing orders enabling pharmacist flu test‑and‑treat (2025)

Assessment

Bottom‑line analytical stance (not advocacy).

Neutral. The bill targets a narrow, time‑sensitive slice of ambulatory care. Expected near‑term effects are improved access and faster treatment for select respiratory infections, with plausible clinical benefits for high‑risk patients. Fiscal and system‑level effects are uncertain: prior experience with convenient low‑acuity sites points to induced demand that can offset substitution savings, and equity benefits will depend on local pharmacy availability and state‑scope alignment. Overall impact will hinge on implementation details (protocols, stewardship, reporting) and whether states and payers harmonize rules to avoid fragmented care. [2]CDC MMWR — Paxlovid Associated with Decreased Hospitalization Rate — MMWR 71(48…

Sourcing (selected)

Authoritative sources underlying this analysis.

• Bill text and payment mechanics: H.R. 3164 introduced text and applicability date/payment formulas. [1]Congress.gov / GPO — BILLS-119hr3164ih.pdf (Official bill text)
• Official status/CBO: Congress.gov docket (as of May 23, 2026) shows status “Introduced,” CBO estimate unavailable. [5]Congress.gov / Library of Congress — H.R. 3164 – Congress.gov overview (status;…
• Access context: HRSA HPSA statistics; pharmacy proximity estimates; pharmacy‑desert literature and closures; telepharmacy policy effects. [9]HRSA Data — HRSA Designated HPSA Quarterly Summary (as of Mar 31, 2026)
• Clinical effectiveness: Paxlovid real‑world effectiveness and prescribing inequities; FDA EUA enabling pharmacist prescribing. [2]CDC MMWR — Paxlovid Associated with Decreased Hospitalization Rate — MMWR 71(48…
• Economic evidence: Retail‑clinic utilization/spending; mixed ED diversion findings; pharmacist chronic‑care meta‑analysis and U.S. cost‑effectiveness modeling. [3]Health Affairs (via PubMed) — Retail Clinic Visits For Low‑Acuity Conditions In…
• Environmental factor: EPA grams CO2 per mile. [16]U.S. EPA — Greenhouse Gas Emissions from a Typical Passenger Vehicle
• Pharmacy‑based vaccination access among Medicare beneficiaries; ongoing PREP Act vaccination authority through 2029. [11]Vaccine (Elsevier) via PMC — Characteristics of older Medicare beneficiaries re…